KCNRG: Potassium Channel Regulatory Protein

Introduction and Summary

KCNRG (Potassium Channel Regulator, also known as CLLD4) is a human protein encoded by the gene located at chromosome 13q14.3, a region frequently deleted in B-cell chronic lymphocytic leukemia (B-CLL) and other malignancies [ivanov-2003-kcnrg-discovery-abstract]. The protein functions as a negative regulator of voltage-gated potassium channels, specifically members of the Kv1 (Shaker) family, by sequestering channels in the endoplasmic reticulum and preventing their surface expression [usman-2010-kcnrg-shaker-abstract]. KCNRG is a 272-amino acid protein containing a BTB/POZ domain homologous to the tetramerization (T1) domain of voltage-gated potassium channels, through which it interacts with and inhibits channel function [ivanov-2003-kcnrg-discovery-abstract].

The protein has emerged as a multifaceted molecule with roles extending beyond simple potassium channel regulation. It functions as a putative tumor suppressor, with overexpression leading to growth inhibition, cell cycle arrest, and apoptosis induction through suppression of mTOR and VEGFR2 signaling pathways [birerdinc-2010-kcnrg-tumor-suppressor-abstract]. Additionally, KCNRG has been identified as a tissue-specific autoantigen in autoimmune polyendocrine syndrome type 1 (APS-1), where autoantibodies against this protein are strongly associated with pulmonary disease [alimohammadi-2009-aps1-autoantigen-abstract].

Gene and Protein Structure

The KCNRG gene is located on chromosome 13q14.2-14.3, spanning positions 50,015,444 to 50,020,922 on the GRCh38 reference assembly (NCBI Gene ID: 283518). The gene comprises three exons and produces two protein isoforms through alternative splicing: KCNRG-L (272 amino acids, ~31 kDa) and KCNRG-S (229 amino acids), which differ in their C-terminal sequences while sharing a common N-terminal region of 184 amino acids [ivanov-2003-kcnrg-discovery-abstract]. The gene overlaps with TRIM13 on the same strand and has been assigned the aliases CLLD4 (Chronic Lymphocytic Leukemia Deletion region gene 4) and DLTET.

The defining structural feature of KCNRG is its N-terminal BTB (Bric-a-brac, Tramtrack, Broad complex) domain, also called the POZ domain, which spans amino acid residues 5-106 (InterPro domains: IPR000210 for BTB/POZ_dom, IPR003131 for T1-type BTB). This domain is homologous to the tetramerization (T1) domain found in voltage-gated potassium channels such as those of the Kv1 (Shaker) family [usman-2010-kcnrg-shaker-abstract]. The T1 domain in potassium channels normally mediates the assembly of four alpha-subunits into functional tetrameric channels, and the structural similarity of KCNRG's BTB domain to this region enables it to interact with and interfere with channel assembly.

Recent AlphaFold structural predictions have provided insights into the oligomeric state of KCNRG. These computational analyses predict that KCNRG forms pentameric structures with C5 symmetry, and molecular dynamics simulations over 200 nanoseconds have validated the stability of this pentameric state [esposito-2022-alphafold-kctd-abstract]. KCNRG has been classified within Cluster 2 of the KCTD protein family based on structural analysis, sharing this cluster with KCTD6, KCTD11, and KCTD21. The C-terminal domain (CTD) of KCNRG adopts a propeller-like structure with a central cavity delimited by five exposed and regular beta-strands, a feature shared with other KCTD family members despite the absence of sequence similarity [esposito-2022-alphafold-kctd-abstract].

Molecular Function: Potassium Channel Regulation

The primary molecular function of KCNRG is the negative regulation of voltage-gated potassium channels, specifically the Kv1 (Shaker) family. Usman and Mathew (2010) provided definitive experimental evidence for this function using Xenopus oocyte expression systems. They demonstrated that KCNRG reduces K+ currents through human potassium channels hKv1.1 (KCNA1) and hKv1.4 (KCNA4) when co-expressed in oocytes [usman-2010-kcnrg-shaker-abstract]. This current attenuation is dependent on the N-terminal T1 domain of the channels, as immunoprecipitation experiments confirmed direct physical association between KCNRG and the N-terminus of these channel proteins.

The mechanism by which KCNRG inhibits channel function involves retention of Kv1 family channels within endomembrane compartments. KCNRG has been characterized as an endoplasmic reticulum (ER)-associated protein, and it appears to function by sequestering a fraction of potassium channels in the ER rather than allowing their trafficking to the plasma membrane [usman-2010-kcnrg-shaker-abstract]. This ER retention mechanism effectively reduces the number of functional channels at the cell surface and consequently decreases whole-cell potassium currents.

The proposed molecular mechanism involves competitive binding of KCNRG's BTB domain to the T1 domains of Kv channels during channel assembly. Since the T1 domain of Kv channels mediates the tetramerization required for functional channel formation, KCNRG may interfere with proper channel assembly by forming heteromeric complexes with channel subunits. This interpretation is supported by the structural homology between KCNRG's BTB domain and the T1 tetramerization domain of voltage-gated potassium channels. KCNRG is one of only two KCTD family proteins known to interact directly with Kv channels, making it a unique regulatory molecule within this protein family.

The original characterization by Ivanov et al. (2003) demonstrated that KCNRG suppresses K+ channel activity in the human prostate cell line LNCaP using electrophysiological techniques [ivanov-2003-kcnrg-discovery-abstract]. This functional effect has implications for cell proliferation, as potassium channels play important roles in cell cycle progression, and their pharmacological blockade has been shown to suppress cellular proliferation.

Subcellular Localization

KCNRG is predominantly localized to the endoplasmic reticulum, consistent with its role in retaining potassium channels within this compartment [usman-2010-kcnrg-shaker-abstract]. This ER localization has been confirmed through multiple experimental approaches including immunofluorescence and biochemical fractionation studies. The ER localization is functionally significant because it positions KCNRG at the site of potassium channel biosynthesis and initial assembly, enabling it to intercept and retain newly synthesized channels before they can traffic to the plasma membrane.

Gene Ontology annotations support the ER localization and characterize KCNRG as having identical protein binding capability and the ability to undergo protein homooligomerization. The protein's association with the ER membrane system rather than the plasma membrane distinguishes it from classical potassium channel subunits and reflects its regulatory rather than channel-forming function.

Tissue Expression Pattern

KCNRG exhibits a tissue-enriched expression pattern, with notably high expression in the fallopian tube compared to other tissues (Tau specificity score of 0.84 according to the Human Protein Atlas). RNA expression levels show the fallopian tube at 33.6 nTPM (normalized transcripts per million), substantially higher than the next highest tissues: lung (2.9 nTPM), testis (2.1 nTPM), and bone marrow (1.8 nTPM). This expression pattern has led to the gene's classification within the "Ciliated tissues - Cilium organization" expression cluster, suggesting a potential role in ciliary structure or function in reproductive and respiratory epithelia.

The original characterization by Ivanov et al. (2003) noted that KCNRG transcripts are expressed in normal tissues and in some tumor cell lines [ivanov-2003-kcnrg-discovery-abstract]. Subsequent studies have identified predominant expression in lung tissue, with additional expression in liver and other tissues at lower levels. This lung expression pattern is particularly relevant to the identification of KCNRG as a bronchial autoantigen in APS-1, where the protein's expression was found to be predominantly restricted to the epithelial cells of terminal bronchioles [alimohammadi-2009-aps1-autoantigen-abstract].

Tumor Suppressor Function and Signaling Pathways

KCNRG has been extensively characterized as a candidate tumor suppressor gene based on its chromosomal location in a frequently deleted region in B-CLL and its functional effects on cell proliferation and apoptosis. Birerdinc et al. (2010) provided comprehensive evidence for the tumor suppressor function of KCNRG through stable overexpression studies in multiple cancer cell lines: RPMI-8226 (multiple myeloma), HL-60 (acute promyelocytic leukemia), and LnCaP (prostate cancer) [birerdinc-2010-kcnrg-tumor-suppressor-abstract].

Overexpression of the longer KCNRG isoform (KCNRG-L) produced significant growth inhibition: 37% reduction in RPMI-8226 (p<0.001), 26% in HL-60 (p<0.0025), and 38% in LnCaP (p<0.009). The shorter isoform (KCNRG-S) showed lesser but still detectable effects on cell growth [birerdinc-2010-kcnrg-tumor-suppressor-abstract]. Beyond growth suppression, KCNRG overexpression dramatically enhanced apoptotic activity: KCNRG-L induced a 180% increase in apoptosis in RPMI-8226, 216% in HL-60, and 46% in LnCaP cells. Additional cellular effects included cell cycle arrest at the G2 phase, morphological changes in suspension cells, and reduced migration capacity.

The molecular mechanisms underlying these tumor suppressor effects involve modulation of key signaling pathways. Proteomics analysis using reverse phase protein arrays revealed that overexpression of either KCNRG isoform was associated with decreased activation of mTOR (mammalian target of rapamycin) through reduced phosphorylation at serines 2481 and 2448 [birerdinc-2010-kcnrg-tumor-suppressor-abstract]. Additionally, decreased phosphorylation of tyrosine 1175 in VEGFR2 (vascular endothelial growth factor receptor 2) was observed. These findings are significant because mTOR and VEGFR2 are central regulators of cell proliferation, survival, and angiogenesis, and their inhibition by KCNRG explains the antiproliferative and pro-apoptotic effects observed.

In RPMI-8226 cells, KCNRG overexpression led to coordinated activation of the apoptotic cascade, with increased cleavage of caspases 3, 6, 7, and 9, as well as the caspase substrate PARP (poly-ADP ribose polymerase) [birerdinc-2010-kcnrg-tumor-suppressor-abstract]. This caspase activation pattern indicates engagement of the intrinsic (mitochondrial) apoptotic pathway, consistent with the effects of mTOR inhibition on cell survival signaling.

Disease Associations

B-Cell Chronic Lymphocytic Leukemia and Multiple Myeloma

The chromosomal region 13q14, where KCNRG is located, represents the most frequently deleted region in B-cell chronic lymphocytic leukemia (affecting approximately 55% of CLL patients), with deletions also commonly observed in multiple myeloma, mantle cell lymphoma (38%), and several solid tumors including prostate cancer [ivanov-2003-kcnrg-discovery-abstract, birerdinc-2010-kcnrg-tumor-suppressor-abstract, lia-2012-13q14-mouse-model-abstract]. Extensive characterization of 13q14 deletions has revealed heterogeneous breakpoints affecting multiple genes. A minimal deleted region (MDR) has been defined that encompasses the DLEU2 gene (encoding a non-coding RNA) and the miR-15a/16-1 microRNA cluster located within a DLEU2 intron. Importantly, KCNRG is encoded within an intron of DLEU2 in humans, placing it within this critical tumor suppressor locus [lia-2012-13q14-mouse-model-abstract].

Functional dissection of this locus using transgenic mouse models has demonstrated that deletion of the MDR containing DLEU2/miR-15a/16-1 replicates CLL-associated lymphoproliferations, while larger deletions encompassing the common deleted region (CDR) produce more aggressive disease phenotypes with faster progression [lia-2012-13q14-mouse-model-abstract]. This finding suggests that multiple tumor suppressors cooperate within this region, and the size of 13q14 deletions influences disease severity. While miR-15a/16-1 (which targets BCL2) has been established as a key tumor suppressor in this locus, the contribution of KCNRG and other genes remains an area of active investigation.

Expression analysis in diffuse large B-cell lymphomas (DLBL) revealed decreased levels of both KCNRG mRNA isoforms compared to normal peripheral blood lymphocytes, with the major isoform showing lower expression in DLBL and the minor isoform decreased across a broad range of lymphoma types [birerdinc-2010-kcnrg-tumor-suppressor-abstract]. The haploinsufficiency model has been proposed, whereby loss of one KCNRG allele through deletion may be relevant to disease progression in at least a subset of CLL and MM patients, potentially cooperating with loss of miR-15a/16-1 to produce more aggressive malignancies.

Hepatocellular Carcinoma

Cho et al. (2006) conducted a comprehensive genetic and expression analysis of KCNRG in hepatocellular carcinomas (HCCs), providing evidence for its role as a tumor suppressor in this malignancy [cho-2006-kcnrg-hcc-abstract]. They identified a missense mutation at codon 92 (CGT→CAT, Arg→His) within the T1 domain of KCNRG. Functional analysis demonstrated that the suppressive cell growth activity of this mutant KCNRG was significantly reduced compared to wild-type protein, indicating that the R92H mutation impairs tumor suppressor function.

Loss of heterozygosity (LOH) at the KCNRG locus was detected in 26.5% of informative HCC cases (17/64), and notably, LOH occurred exclusively in hepatitis B virus (HBV)-positive tumors [cho-2006-kcnrg-hcc-abstract]. This LOH was significantly correlated with adverse clinicopathological features including intrahepatic metastasis (p=0.0247), higher tumor grade (p=0.0078), and advanced clinical stage (p=0.0071). Expression analysis revealed loss of KCNRG transcript in 22 tumor tissues, further supporting a role for KCNRG inactivation in HCC progression.

Autoimmune Polyendocrine Syndrome Type 1

In a distinct disease context, Alimohammadi et al. (2009) identified KCNRG as a tissue-specific autoantigen in autoimmune polyendocrine syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) [alimohammadi-2009-aps1-autoantigen-abstract]. This rare autoimmune disorder is caused by mutations in the AIRE (autoimmune regulator) gene, leading to failure of central immune tolerance and development of multiple organ-specific autoantibodies.

Through immunoscreening of a cDNA library using serum from an APS-1 patient with obstructive respiratory symptoms, KCNRG was identified as a pulmonary autoantigen. Testing of 110 APS-1 patients revealed a striking correlation: autoantibodies to KCNRG were present in 7 of 8 patients with respiratory symptoms but in only 1 of 102 patients without respiratory involvement [alimohammadi-2009-aps1-autoantigen-abstract]. The study described eight APS-1 patients with respiratory symptoms, four of whom had severe airway obstruction, and two died from respiratory disease.

Immunohistochemical analysis demonstrated that KCNRG expression is predominantly restricted to the epithelial cells of terminal bronchioles, explaining the specificity of pulmonary manifestations in patients with anti-KCNRG autoantibodies [alimohammadi-2009-aps1-autoantigen-abstract]. This tissue-restricted expression pattern identifies the terminal bronchiole as a previously unrecognized autoimmune target in APS-1. Anti-KCNRG autoantibodies have been proposed as a biomarker for identifying APS-1 patients at risk for pulmonary disease, and successful treatment with rituximab has been reported in affected patients.

Mouse Models and Conservation

The mouse ortholog of KCNRG (MGI:2685591) is located on chromosome 14 and shares conserved BTB/POZ domain architecture with the human protein. The Mouse Genome Informatics database documents 9 total mutations and alleles for mouse Kcnrg, including 6 targeted alleles, 1 gene-trapped allele, 1 endonuclease-mediated allele, and 1 chemically-induced allele, with 17 mouse strains or lines available through the International Mouse Strain Resource (IMSR). Expression studies have documented 706 assay results for Kcnrg in the Gene Expression Database (GXD), with expression detected across multiple developmental stages and anatomical structures including the nervous system and cardiovascular system during embryonic development.

While specific phenotype data for KCNRG knockout mice have not been extensively published in the literature, the functional dissection of the 13q14 locus using transgenic mouse models by Lia et al. (2012) demonstrated that deletions encompassing the common deleted region (which includes the KCNRG locus) produced more aggressive lymphoproliferative disease compared to deletions of the minimal deleted region alone [lia-2012-13q14-mouse-model-abstract]. This suggests that KCNRG, along with other genes in this region, contributes to the tumor suppressor function of the 13q14 locus, though disentangling the specific contribution of individual genes remains challenging given their physical overlap and potential functional redundancy.

KCTD Protein Family Context

KCNRG belongs to the KCTD (potassium channel tetramerization domain) protein family, which comprises 25 members (KCTD1-21, KCNRG, SHKBP1, TNFAIP1, and BTBD10) characterized by an N-terminal domain homologous to the T1 tetramerization domain of voltage-gated potassium channels [liu-2013-kctd-family-review-abstract]. The BTB domain that defines this family is a highly conserved motif of approximately 100 amino acids that mediates protein-protein interactions and oligomerization.

While many KCTD family members function as substrate adaptors for Cullin3-based E3 ubiquitin ligases, KCNRG appears to have a distinct functional role centered on potassium channel regulation. KCNRG is one of only two KCTD proteins known to interact directly with Kv channels, the other being KCTD5 which has been shown to have different functional outcomes. The KCTD family review by Liu et al. (2013) classified members into seven phylogenetic groups based on BTB domain sequence similarity [liu-2013-kctd-family-review-abstract], though KCNRG's classification within this scheme varies between studies.

Structure-based classification using AlphaFold predictions places KCNRG in Cluster 2 along with KCTD6, KCTD11, and KCTD21 [esposito-2022-alphafold-kctd-abstract]. Interestingly, the other members of this cluster (KCTD11 and KCTD21) have been shown to downregulate histone deacetylase (HDAC) activity, raising the question of whether KCNRG may have similar capabilities that have yet to be characterized.

Open Questions

Several important questions remain regarding KCNRG function and its role in disease:

1. Structural basis of channel interaction: While it is established that KCNRG interacts with Kv1 channels via T1 domain interactions, the precise structural basis for this interaction and how it leads to ER retention of channels remains to be elucidated. High-resolution structures of KCNRG-channel complexes would be valuable.

2. Mechanism linking channel regulation to tumor suppression: The relationship between KCNRG's potassium channel regulatory function and its tumor suppressor activity is not fully understood. While potassium channels are known to influence cell proliferation, the precise mechanistic link between channel inhibition and the observed effects on mTOR/VEGFR2 signaling requires further investigation.

3. Possible HDAC regulatory function: Given that KCNRG clusters structurally with KCTD proteins that regulate HDAC activity, it would be valuable to determine whether KCNRG also possesses HDAC regulatory capabilities, which could provide an additional mechanism for its tumor suppressor function.

4. Cullin3 interaction: While many KCTD family members function as Cullin3 adaptors for E3 ubiquitin ligases, whether KCNRG has this capability and what substrates it might target for ubiquitination remains unexplored.

5. Role in ciliated epithelia: The enriched expression of KCNRG in fallopian tube and its classification in the "cilium organization" expression cluster suggests possible roles in ciliary function that have not been characterized.

6. Pathogenic role of anti-KCNRG autoantibodies: While anti-KCNRG antibodies are strongly associated with pulmonary disease in APS-1, whether these antibodies are directly pathogenic or merely markers of tissue damage requires further study. The mechanism by which loss of immune tolerance to KCNRG leads to respiratory disease is not fully understood.

7. Therapeutic potential: The tumor suppressor function of KCNRG raises the possibility of therapeutic strategies based on restoring or enhancing its activity in cancers with 13q14 deletions. The druggability of this pathway and potential approaches to modulate KCNRG function remain to be explored.

References

1. ivanov-2003-kcnrg-discovery-abstract: Ivanov DV, Tyazhelova TV, Lemonnier L, Kononenko N, Pestova AA, Nikitin EA, Prevarskaya N, Skryma R, Panchin YV, Yankovsky NK, Baranova AV. A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3. FEBS Letters. 2003;539(1-3):156-60. PMID: 12650944. DOI: 10.1016/s0014-5793(03)00211-4. https://pubmed.ncbi.nlm.nih.gov/12650944/

2. usman-2010-kcnrg-shaker-abstract: Usman H, Mathew MK. Potassium channel regulator KCNRG regulates surface expression of Shaker-type potassium channels. Biochemical and Biophysical Research Communications. 2010;391(3):1301-5. PMID: 19968958. DOI: 10.1016/j.bbrc.2009.11.143. https://pubmed.ncbi.nlm.nih.gov/19968958/

3. birerdinc-2010-kcnrg-tumor-suppressor-abstract: Birerdinc A, Nober T, Engel M, Goheer Agha RA, Engel H, Mottershead C, Baranova A. Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region. Tumour Biology. 2010;31(1):33-45. PMID: 20237900. PMCID: PMC2803748. DOI: 10.1007/s13277-009-0005-0. https://pmc.ncbi.nlm.nih.gov/articles/PMC2803748/

4. alimohammadi-2009-aps1-autoantigen-abstract: Alimohammadi M, Dubois N, Sköldberg F, et al. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proceedings of the National Academy of Sciences U.S.A. 2009;106(11):4396-401. PMID: 19251657. PMCID: PMC2648890. DOI: 10.1073/pnas.0809986106. https://pubmed.ncbi.nlm.nih.gov/19251657/

5. cho-2006-kcnrg-hcc-abstract: Cho YG, Kim CJ, Song JH, Rhie DJ, Park YK, Kim SY, Nam SW, Yoo NJ, Lee JY, Park WS. Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas. Experimental & Molecular Medicine. 2006;38(3):247-55. PMID: 16819283. DOI: 10.1038/emm.2006.30. https://pubmed.ncbi.nlm.nih.gov/16819283/

6. esposito-2022-alphafold-kctd-abstract: Esposito L, Balasco N, Vitagliano L. Alphafold Predictions Provide Insights into the Structural Features of the Functional Oligomers of All Members of the KCTD Family. International Journal of Molecular Sciences. 2022;23(21):13346. PMID: 36362127. PMCID: PMC9658877. DOI: 10.3390/ijms232113346. https://pmc.ncbi.nlm.nih.gov/articles/PMC9658877/

7. liu-2013-kctd-family-review-abstract: Liu Z, Xiang Y, Sun G. The KCTD family of proteins: structure, function, disease relevance. Cell & Bioscience. 2013;3(1):45. PMID: 24268103. PMCID: PMC3882106. DOI: 10.1186/2045-3701-3-45. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882106/

8. lia-2012-13q14-mouse-model-abstract: Lia M, Carette A, Tang H, Shen Q, Mo T, Bhagat G, Dalla-Favera R, Klein U. Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood. 2012;119(13):2981-90. PMID: 22174151. DOI: 10.1182/blood-2011-09-381814. https://pubmed.ncbi.nlm.nih.gov/22174151/

Database Resources

• UniProt: Q8N5I3 - https://www.uniprot.org/uniprotkb/Q8N5I3
• NCBI Gene: 283518 - https://www.ncbi.nlm.nih.gov/gene/283518
• Human Protein Atlas: ENSG00000198553 - https://www.proteinatlas.org/ENSG00000198553-KCNRG
• GeneCards: KCNRG - https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG
• Mouse Genome Informatics (MGI): MGI:2685591 - https://www.informatics.jax.org/marker/MGI:2685591

Citations

1. alimohammadi-2009-aps1-autoantigen-abstract.md
2. birerdinc-2010-kcnrg-tumor-suppressor-abstract.md
3. cho-2006-kcnrg-hcc-abstract.md
4. esposito-2022-alphafold-kctd-abstract.md
5. ivanov-2003-kcnrg-discovery-abstract.md
6. lia-2012-13q14-mouse-model-abstract.md
7. liu-2013-kctd-family-review-abstract.md
8. usman-2010-kcnrg-shaker-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview: We verified KCNRG identity and organism, collected and analyzed foundational and recent sources (prioritizing 2023–2024), extracted mechanistic, localization, and disease-association evidence, and synthesized findings into a structured, well-cited report.

Research report: Human KCNRG (UniProt Q8N5I3)

1) Key concepts and definitions
- Identity and genomic context: KCNRG encodes a potassium channel regulatory protein within the chromosome 13q14.3 region frequently deleted in B‑cell malignancies. It lies adjacent to RFP2 and can be transcribed independently; the protein contains a single T1 (tetramerization) domain, which is distantly related to the BTB/POZ domain class that mediates protein–protein interactions. This domain is the N‑terminal cytoplasmic tetramerization module used by voltage‑gated K+ channel α‑subunits (Kv) to assemble, suggesting a mechanism for channel regulation (Molecular Biology, Mar 2004; URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa) (baranova2004structuralandfunctional pages 5-6).
- Isoforms and family: KCNRG produces two human protein isoforms sharing the common N‑terminus that includes the T1 domain: KCNRG‑L (272 aa) and KCNRG‑S (229 aa). KCNRG belongs to the non-channel T1/BTB (KCTD) family of proteins. In human tissues, the KCNRG‑L transcript is substantially more abundant than KCNRG‑S (reported ~300-fold higher mRNA) (Tumour Biology, Dec 2010 online Dec 18, 2009; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 5-7).
- Core concept of function: Based on homology to Kv tetramerization domains and experimental data with overexpression, KCNRG is proposed to bind Kv channel T1 domains and disrupt normal tetramer assembly/trafficking, thereby suppressing Kv currents (Tumour Biology, Dec 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 1-2).

2) Recent developments and latest research (emphasis 2023–2024)
- APS‑1 cohorts and pulmonary autoimmunity: A 2024 prospective longitudinal French APECED/APS‑1 cohort (n=25) emphasized non‑endocrine manifestations including pulmonary involvement and referenced the clinical use of KCNRG autoantibodies (together with BPIFB1) as a lung disease marker in APS‑1, consistent with earlier work. Systematic immunologic profiling highlighted broad autoantibody spectra and frequent pulmonary involvement on screening (The Journal of Clinical Endocrinology & Metabolism, Apr 2024; URL: https://doi.org/10.1210/clinem/dgae211) (humbert2024lessonsfromprospective pages 10-12).
- Differential autoantibody landscapes in APS‑like phenotypes: A 2023 report of an APECED‑like case due to a de novo FAM111B variant (POIKTMP) specifically tested for APS‑1 pneumonitis autoantibodies and found BPIFB1 and KCNRG autoantibodies were not detected, underscoring that KCNRG autoantibodies are more characteristic of AIRE‑deficient APS‑1 pneumonitis and not universal to APS‑like diseases (Frontiers in Immunology, Feb 2023; URL: https://doi.org/10.3389/fimmu.2023.1133387) (ferre2023casereportdiscovery pages 3-5).
- Platelet ion channelome context (2021, integrative review with data tables): KCNRG appears in a curated list of “channel regulatory proteins” detected at transcriptomic level in human platelets, alongside Kv1.3 and accessory subunits (Platelets, Apr 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 1-3, wright2021whydoplatelets pages 3-4).

3) Molecular function, pathways, and localization
- Mechanism inferred from domain architecture and functional assays: KCNRG contains an N‑terminal cytoplasmic T1 domain homologous to Kv α‑subunit tetramerization domains. This suggests KCNRG can interact with Kv α‑subunits, perturb assembly of functional tetramers, and consequently reduce surface expression and ionic current. Supporting experiments show that overexpression of KCNRG isoforms in human cell lines reduces proliferation and induces apoptosis; the authors propose suppression of Kv currents via interference with T1‑mediated α‑subunit assembly (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 1-2, birerdinc2010proapoptoticandantiproliferative pages 5-7).
- Subcellular localization: KCNRG is described as a cytoplasmic protein with the T1/BTB-like domain; its mechanism implies interaction with Kv channels early in the biosynthetic pathway where tetramerization occurs (in cytoplasm/near ER entry), consistent with T1 domain biology (Molecular Biology, 2004; URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa) (baranova2004structuralandfunctional pages 5-6). Direct subcellular imaging for KCNRG is limited in available literature.
- Tissue expression and cellular sites of action: KCNRG transcripts are co-expressed across human tissues with KCNRG‑L dominant. Notably, in APS‑1 pulmonary disease, KCNRG antigen is enriched in epithelial cells of terminal bronchioles, consistent with its role as an autoantigen in pneumonitis (Pediatric Pulmonology, Jan 2012 online Sep 7, 2011; URL: https://doi.org/10.1002/ppul.21520) (popler2012autoimmunepolyendocrinesyndrome pages 1-3). In platelets, KCNRG is reported at transcript level as an accessory/regulatory protein candidate (Platelets, 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 3-4).

4) Disease associations and clinical relevance
- 13q14 deletion in CLL and MM; putative tumor suppressor: KCNRG resides in the minimal deleted region at 13q14.3 frequently lost in B‑cell chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Overexpression studies in RPMI‑8226 (MM), HL‑60 (myeloid), and LNCaP (prostate) cells demonstrated growth suppression and pro‑apoptotic effects, with caspase 3/6/7/9 and PARP cleavage; KCNRG‑L overexpression caused G2 arrest and reduced cell migration. Clinical expression profiling showed KCNRG‑L mRNA significantly lower in diffuse large B‑cell lymphoma than normal peripheral blood lymphocytes (P<0.002), and stage‑associated decreases across lymphoma cohorts, supporting a tumor suppressor role and possible haploinsufficiency mechanism in 13q14 loss contexts (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 12-13, birerdinc2010proapoptoticandantiproliferative pages 1-2). Earlier mapping work positioned KCNRG within 13q14.3 near RFP2, a region repeatedly implicated in CLL (Molecular Biology, 2004; URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa) (baranova2004structuralandfunctional pages 5-6).
- APS‑1 (AIRE deficiency) pulmonary disease: KCNRG is a recognized pulmonary autoantigen in APS‑1, with autoantibodies serving as a biomarker of active bronchiolitis/pneumonitis. In a pediatric APS‑1 case with severe pulmonary disease, KCNRG autoantibodies were positive and guided B‑cell–targeted therapy; rituximab improved symptoms, oxygen need, and obstruction on PFTs despite unchanged autoantibody titers, supporting clinical utility as a disease activity marker rather than a pharmacodynamic readout (Pediatric Pulmonology, 2012; URL: https://doi.org/10.1002/ppul.21520) (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4). The 2024 French APS‑1 cohort reinforces the prominence of non‑endocrine manifestations including pulmonary disease and references KCNRG/BPIFB1 serology in surveillance (JCEM, 2024; URL: https://doi.org/10.1210/clinem/dgae211) (humbert2024lessonsfromprospective pages 10-12). A 2023 APS‑like POIKTMP case lacked KCNRG autoantibodies, underscoring syndrome specificity (Frontiers in Immunology, 2023; URL: https://doi.org/10.3389/fimmu.2023.1133387) (ferre2023casereportdiscovery pages 3-5).

5) Quantitative and experimental details
- Isoform abundance: KCNRG‑L mRNA ~300× higher than KCNRG‑S in human tissues examined (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12).
- Lymphoma expression and statistics: KCNRG‑L downregulated in diffuse large B‑cell lymphoma relative to normal PBLs (P<0.002), with stage‑linked reductions across cohorts; KCNRG‑S also decreased in early and IIE stages (reported P<0.008 and P<0.04, respectively) (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12).
- Functional phenotypes upon overexpression: In RPMI‑8226 and HL‑60 cells, KCNRG overexpression triggered apoptosis (caspase 3/6/7/9 and PARP cleavage), G2 arrest, reduced migration, and stress‑induced cell death propensity; methods included BrdU proliferation ELISA, CaspaseGLO 3/7 assays, Annexin V/7‑AAD FACS, and reverse‑phase protein microarrays indicating suppression of mTOR/VEGFR signaling (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 12-13, birerdinc2010proapoptoticandantiproliferative pages 2-4).
- APS‑1 pulmonary disease biomarkers and outcomes: In the 2012 case, KCNRG autoantibody positivity associated with bronchiolitis/bronchiectasis on CT, lymphoid aggregates on biopsy, and clinical improvement after rituximab, while an APS‑1 control without lung disease lacked KCNRG autoantibodies (Pediatric Pulmonology, 2012; URL: https://doi.org/10.1002/ppul.21520) (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4). In the 2024 prospective APS‑1 cohort, 8/13 patients with lung function tests had impaired LFTs at baseline, highlighting frequent pulmonary involvement and the importance of systematic screening (JCEM, 2024; URL: https://doi.org/10.1210/clinem/dgae211) (humbert2024lessonsfromprospective pages 10-12).
- Platelet context: Kv1.3/KCa3.1 dominate platelet K+ conductances; KCNRG is listed among channel regulatory proteins detected at the transcript level in platelets, suggesting potential broader hematologic relevance though direct function in platelets remains to be established (Platelets, 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 3-4).

6) Current applications and real‑world implementations
- Clinical serology in APS‑1: KCNRG autoantibody testing is used in specialized centers to identify APS‑1 patients at risk for or with active pneumonitis/bronchiolitis, often alongside BPIFB1; positive serology may support initiating B‑cell–directed therapy (e.g., rituximab) when infection is excluded and histology shows lymphoid aggregates (Pediatric Pulmonology, 2012; URL: https://doi.org/10.1002/ppul.21520; JCEM, 2024; URL: https://doi.org/10.1210/clinem/dgae211) (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4, humbert2024lessonsfromprospective pages 10-12).
- Oncology research: KCNRG is a putative tumor suppressor candidate in the 13q14 deletion landscape of CLL/MM. Expression profiling and functional overexpression studies inform biomarker exploration and mechanistic hypotheses for haploinsufficiency in B‑cell malignancies (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 10-12, birerdinc2010proapoptoticandantiproliferative pages 12-13).

7) Expert opinions and analysis
- Domain‑based inference supports a model in which KCNRG acts as a soluble T1‑domain decoy/modulator for Kv α‑subunits, potentially limiting Kv channel assembly, surface trafficking, and current. The resulting effects—altered membrane potential, reduced Kv‑dependent signaling—could contribute to growth suppression and apoptosis observed upon overexpression. While direct electrophysiological suppression is proposed and patch‑clamp confirmation is referenced, detailed current magnitudes and channel‑specific partners remain to be comprehensively mapped in primary human cells (Molecular Biology, 2004; Tumour Biology, 2010; URLs above) (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 2-4).
- In APS‑1, the emergence of KCNRG autoantibodies appears linked to bronchiolar epithelium autoimmunity. The 2024 prospective cohort underscores frequent non‑endocrine involvement and supports systematic surveillance including pulmonary evaluation and autoantibody testing, aligning with prior single‑center experiences using KCNRG/BPIFB1 serology to stratify lung disease risk and monitor activity (JCEM, 2024; Pediatric Pulmonology, 2012; URLs above) (humbert2024lessonsfromprospective pages 10-12, popler2012autoimmunepolyendocrinesyndrome pages 1-3).

8) Limitations and open questions
- Precise subcellular localization and partner mapping for KCNRG in native human cells require further study. Direct biochemical evidence for KCNRG–Kv T1 interactions and quantitative current suppression in primary cells are limited in the available literature; most functional data derive from overexpression systems (Tumour Biology, 2010; URL: https://doi.org/10.1007/s13277-009-0005-0) (birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 10-12).
- The breadth of tissues expressing KCNRG protein (beyond mRNA) and its physiological roles in non‑disease settings remain incompletely defined. Platelet data list KCNRG at transcript level only, and functional roles in hematologic cells are not yet established (Platelets, 2021; URL: https://doi.org/10.1080/09537104.2021.1904135) (wright2021whydoplatelets pages 3-4).

Compliance with identification checks
- Gene symbol and protein match: Literature identifies KCNRG as “potassium channel‑regulating gene/protein” in human, aligning with the UniProt description and organism (Homo sapiens) (Molecular Biology, 2004; Tumour Biology, 2010; URLs above) (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 1-2).
- Domains: KCNRG contains a single T1 domain distantly related to BTB/POZ, consistent with UniProt domain annotations (Molecular Biology, 2004; URL above) (baranova2004structuralandfunctional pages 5-6).
- Ambiguity: No conflicting gene with the KCNRG symbol in human was identified in the cited literature; studies consistently place KCNRG in 13q14.3 and relate to K+ channel regulation (baranova2004structuralandfunctional pages 5-6, birerdinc2010proapoptoticandantiproliferative pages 1-2).

References (URLs and dates)
- Baranova AV et al. Structural and functional characterization of human chromosome 13q14 and its potential tumor suppressor genes. Molecular Biology. Mar 2004. URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa (baranova2004structuralandfunctional pages 5-6).
- Birerdinc A et al. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology. Dec 2010 (online Dec 18, 2009). URL: https://doi.org/10.1007/s13277-009-0005-0 (birerdinc2010proapoptoticandantiproliferative pages 5-7, birerdinc2010proapoptoticandantiproliferative pages 1-2, birerdinc2010proapoptoticandantiproliferative pages 2-4, birerdinc2010proapoptoticandantiproliferative pages 12-13, birerdinc2010proapoptoticandantiproliferative pages 10-12).
- Popler J et al. Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric Pulmonology. Jan 2012 (online Sep 7, 2011). URL: https://doi.org/10.1002/ppul.21520 (popler2012autoimmunepolyendocrinesyndrome pages 1-3, popler2012autoimmunepolyendocrinesyndrome pages 3-4).
- Humbert L et al. Lessons From Prospective Longitudinal Follow‑up of a French APECED Cohort. The Journal of Clinical Endocrinology & Metabolism. Apr 2024. URL: https://doi.org/10.1210/clinem/dgae211 (humbert2024lessonsfromprospective pages 10-12).
- Ferré EMN et al. Case report: Discovery of a de novo FAM111B pathogenic variant in a patient with an APECED‑like clinical phenotype. Frontiers in Immunology. Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133387 (ferre2023casereportdiscovery pages 3-5).
- Wright JR, Mahaut‑Smith MP. Why do platelets express K+ channels? Platelets. Published online Apr 19, 2021. URL: https://doi.org/10.1080/09537104.2021.1904135 (wright2021whydoplatelets pages 1-3, wright2021whydoplatelets pages 3-4).

References

1. (baranova2004structuralandfunctional pages 5-6): A. V. Baranova, D. V. Ivanov, T. V. Tyazhelova, and N. K. Yankovsky. Structural and functional characterization of human chromosome 13q14 and its potential tumor suppressor genes. Molecular Biology, 38:165-173, Mar 2004. URL: https://doi.org/10.1023/b:mbil.0000023730.61501.aa, doi:10.1023/b:mbil.0000023730.61501.aa. This article has 1 citations and is from a peer-reviewed journal.

2. (birerdinc2010proapoptoticandantiproliferative pages 10-12): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

3. (birerdinc2010proapoptoticandantiproliferative pages 5-7): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

4. (birerdinc2010proapoptoticandantiproliferative pages 2-4): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

5. (birerdinc2010proapoptoticandantiproliferative pages 1-2): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

6. (humbert2024lessonsfromprospective pages 10-12): Linda Humbert, Emmanuelle Proust-Lemoine, Sylvain Dubucquoi, Elisabeth Helen Kemp, Pascale Saugier-Veber, Nicole Fabien, Isabelle Raymond-Top, Catherine Cardot-Bauters, Jean-Claude Carel, Maryse Cartigny, Olivier Chabre, Philippe Chanson, Brigitte Delemer, Christine Do Cao, Laurence Guignat, Jean Emmanuel Kahn, Veronique Kerlan, Herve Lefebvre, Agnès Linglart, Roberto Mallone, Rachel Reynaud, Boualem Sendid, Pierre-François Souchon, Philippe Touraine, Jean-Louis Wémeau, and Marie-Christine Vantyghem. Lessons from prospective longitudinal follow-up of a french apeced cohort. The Journal of Clinical Endocrinology & Metabolism, 110:e757-e773, Apr 2024. URL: https://doi.org/10.1210/clinem/dgae211, doi:10.1210/clinem/dgae211. This article has 5 citations.

7. (ferre2023casereportdiscovery pages 3-5): Elise M. N. Ferré, Yunting Yu, Vasileios Oikonomou, Anna Hilfanova, Chyi-Chia R. Lee, Lindsey B. Rosen, Peter D. Burbelo, Sara E. Vazquez, Mark S. Anderson, Amisha Barocha, Theo Heller, Ariane Soldatos, Steven M. Holland, Magdalena A. Walkiewicz, and Michail S. Lionakis. Case report: discovery of a de novo fam111b pathogenic variant in a patient with an apeced-like clinical phenotype. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133387, doi:10.3389/fimmu.2023.1133387. This article has 3 citations and is from a peer-reviewed journal.

8. (wright2021whydoplatelets pages 1-3): Joy R Wright and Martyn P. Mahaut-Smith. Why do platelets express k+ channels? Platelets, 32:872-879, Apr 2021. URL: https://doi.org/10.1080/09537104.2021.1904135, doi:10.1080/09537104.2021.1904135. This article has 16 citations and is from a peer-reviewed journal.

9. (wright2021whydoplatelets pages 3-4): Joy R Wright and Martyn P. Mahaut-Smith. Why do platelets express k+ channels? Platelets, 32:872-879, Apr 2021. URL: https://doi.org/10.1080/09537104.2021.1904135, doi:10.1080/09537104.2021.1904135. This article has 16 citations and is from a peer-reviewed journal.

10. (popler2012autoimmunepolyendocrinesyndrome pages 1-3): Jonathan Popler, Mohammad Alimohammadi, Olle Kämpe, Frida Dalin, Megan K. Dishop, Jennifer M. Barker, Margaret Moriarty‐Kelsey, Jennifer B. Soep, and Robin R. Deterding. Autoimmune polyendocrine syndrome type 1: utility of kcnrg autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric Pulmonology, 47:84-87, Jan 2012. URL: https://doi.org/10.1002/ppul.21520, doi:10.1002/ppul.21520. This article has 55 citations and is from a peer-reviewed journal.

11. (birerdinc2010proapoptoticandantiproliferative pages 12-13): Aybike Birerdinc, Elizabeth Nohelty, Andrey Marakhonov, Ganiraju Manyam, Ivan Panov, Stephanie Coon, Eugene Nikitin, Mikhail Skoblov, Vikas Chandhoke, and Ancha Baranova. Pro-apoptotic and antiproliferative activity of human kcnrg, a putative tumor suppressor in 13q14 region. Tumour Biology, 31:33-45, Dec 2010. URL: https://doi.org/10.1007/s13277-009-0005-0, doi:10.1007/s13277-009-0005-0. This article has 36 citations.

12. (popler2012autoimmunepolyendocrinesyndrome pages 3-4): Jonathan Popler, Mohammad Alimohammadi, Olle Kämpe, Frida Dalin, Megan K. Dishop, Jennifer M. Barker, Margaret Moriarty‐Kelsey, Jennifer B. Soep, and Robin R. Deterding. Autoimmune polyendocrine syndrome type 1: utility of kcnrg autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric Pulmonology, 47:84-87, Jan 2012. URL: https://doi.org/10.1002/ppul.21520, doi:10.1002/ppul.21520. This article has 55 citations and is from a peer-reviewed journal.

Citations

1. baranova2004structuralandfunctional pages 5-6
2. humbert2024lessonsfromprospective pages 10-12
3. ferre2023casereportdiscovery pages 3-5
4. popler2012autoimmunepolyendocrinesyndrome pages 1-3
5. wright2021whydoplatelets pages 3-4
6. birerdinc2010proapoptoticandantiproliferative pages 10-12
7. birerdinc2010proapoptoticandantiproliferative pages 5-7
8. birerdinc2010proapoptoticandantiproliferative pages 2-4
9. birerdinc2010proapoptoticandantiproliferative pages 1-2
10. wright2021whydoplatelets pages 1-3
11. birerdinc2010proapoptoticandantiproliferative pages 12-13
12. popler2012autoimmunepolyendocrinesyndrome pages 3-4
13. https://doi.org/10.1023/b:mbil.0000023730.61501.aa
14. https://doi.org/10.1007/s13277-009-0005-0
15. https://doi.org/10.1210/clinem/dgae211
16. https://doi.org/10.3389/fimmu.2023.1133387
17. https://doi.org/10.1080/09537104.2021.1904135
18. https://doi.org/10.1002/ppul.21520
19. https://doi.org/10.1002/ppul.21520;
20. https://doi.org/10.1023/b:mbil.0000023730.61501.aa,
21. https://doi.org/10.1007/s13277-009-0005-0,
22. https://doi.org/10.1210/clinem/dgae211,
23. https://doi.org/10.3389/fimmu.2023.1133387,
24. https://doi.org/10.1080/09537104.2021.1904135,
25. https://doi.org/10.1002/ppul.21520,

KCNRG (Potassium Channel Regulatory Protein) – Gene Function and Current Insights

Gene Identity and Structure

The KCNRG gene (HGNC:18893) encodes a Potassium Channel Regulatory Protein, also known as CLLD4 (Chronic Lymphocytic Leukemia Deleted gene 4) (www.genecards.org) (www.ncbi.nlm.nih.gov). It is a human protein-coding gene located on chromosome 13q14.3, overlapping the TRIM13 (RFP2) gene on the same strand (www.ncbi.nlm.nih.gov). KCNRG gives rise to multiple mRNA transcripts due to alternative splicing, encoding two main isoforms of 229 and 272 amino acids (www.sciencedirect.com). These isoforms share an identical N-terminus and differ only in their C-terminal region (www.sciencedirect.com). Notably, the KCNRG protein sequence contains a BTB/POZ domain (Broad-Complex, Tramtrack, Bric-à-Brac) homologous to the tetramerization (T1) domain of voltage-gated potassium (K⁺) channels (www.sciencedirect.com). This BTB/POZ domain is a well-known protein-protein interaction module that mediates oligomerization; in Kv channels it enables subunits to assemble into tetramers (www.sciencedirect.com). The presence of this domain in KCNRG immediately suggested it might interface with K⁺ channel subunits (www.sciencedirect.com) (www.sciencedirect.com). Consistent with its lack of any transmembrane segment, KCNRG is a soluble, intracellular protein (www.sciencedirect.com), predicted to reside in the cytoplasm and/or on cytosolic faces of membranes where it can interact with channel proteins.

Verification: The KCNRG symbol is unambiguous for the human gene described above. It should not be confused with similarly named loci in other species. All literature and data cited herein refer to human KCNRG (UniProt Q8N5I3), which contains the BTB/T1 domain and is distinct from other K⁺ channel subunits. The UniProt description “Potassium channel regulatory protein (CLLD4)” matches this gene (www.genecards.org), and the genomic context (13q14.3 in Homo sapiens) is confirmed by multiple sources (www.ncbi.nlm.nih.gov).

Expression and Localization

KCNRG is expressed ubiquitously at the mRNA level, with particularly high expression reported in testis and bone marrow among human tissues (www.ncbi.nlm.nih.gov). Early characterization detected KCNRG transcripts in all normal tissues examined, as well as some tumor cell lines (www.sciencedirect.com) (www.sciencedirect.com). Protein-level analysis has shown KCNRG to be notably present in the lung: it is predominantly expressed in the epithelial cells of terminal bronchioles (pmc.ncbi.nlm.nih.gov). In fact, KCNRG was identified as a bronchial autoantigen – patients with autoimmune polyendocrine syndrome type 1 (APS-1) who develop autoimmune lung disease frequently produce autoantibodies against KCNRG (pmc.ncbi.nlm.nih.gov). This finding indicates KCNRG protein is accessible and immunologically relevant in the lung. Similarly, during acute inflammatory conditions like ARDS (acute respiratory distress syndrome) and sepsis, KCNRG emerges as a common autoantibody target, likely due to lung tissue damage releasing the protein (pmc.ncbi.nlm.nih.gov). Together, these observations underscore that KCNRG protein is expressed in pulmonary tissues and can localize to the bronchial epithelium in vivo (pmc.ncbi.nlm.nih.gov). Given that KCNRG lacks a membrane-spanning region, it is presumed to function on the cytosolic side of cellular membranes. The UniProt curation suggests KCNRG may tether certain K⁺ channels in intracellular compartments (endomembranes), effectively retaining a fraction of channels inside the cell (www.genecards.org). This is consistent with its diffuse cytosolic localization and binding capacity. No evidence points to nuclear localization or DNA/RNA-binding activity – its known interactions are protein-protein in nature (e.g. identical protein binding and likely binding to channel subunits) (www.genecards.org).

Mechanism: Regulation of Potassium Channels

KCNRG’s primary function is to suppress voltage-gated K⁺ channel activity in cells. This was first demonstrated by functional assays: when KCNRG is ectopically expressed in cells, it causes a significant reduction in K⁺ currents through voltage-gated channels (www.sciencedirect.com). For example, in human LNCaP prostate cells, whole-cell patch-clamp recordings showed that introducing KCNRG markedly decreased the K⁺ current density compared to control cells (www.sciencedirect.com). How does KCNRG achieve this inhibition? The current understanding is that KCNRG interferes with the normal assembly of K⁺ channel α-subunits. Voltage-gated K⁺ (Kv) channels are tetramers of pore-forming α-subunits, which rely on their N-terminal T1 domains to co-assemble into a functional channel complex. KCNRG, having a homologous T1 (BTB) domain, likely acts as a competitive binding partner for Kv channel subunits (www.sciencedirect.com) (www.sciencedirect.com). Experimental evidence and homology analysis support this model: KCNRG’s BTB domain shows strong sequence similarity to the Kv1 family T1 domain (e.g., PF02214) (www.sciencedirect.com), suggesting it can bind the same interfaces used by channel subunits during tetramerization. Researchers proposed that KCNRG protein can bind to K⁺ channel subunits via this domain, preventing proper tetramer formation and/or causing misassembly of the channel complex (www.sciencedirect.com). As a result, fewer functional channels reach the plasma membrane, leading to suppressed K⁺ flux. In line with this, hydrophilicity analyses confirm KCNRG is a cytosolic protein, not an ion channel itself, reinforcing that its effect is through channel binding rather than pore formation (www.sciencedirect.com).

The inhibitory impact of KCNRG appears to be selective for certain channel families – it is often described as regulating the Kv1 subfamily of K⁺ channels in particular (www.genecards.org). The UniProt/Swiss-Prot annotation suggests KCNRG may retain a fraction of Kv1 channels in the endoplasmic reticulum or Golgi, thereby reducing surface expression of these channels (www.genecards.org). This mechanism is analogous to having an “intracellular channel blocker” or a dominant-negative subunit. By curtailing K⁺ currents, KCNRG can influence the cell’s membrane potential and downstream signaling. K⁺ channel activity is known to facilitate cell proliferation in many contexts (www.sciencedirect.com). Kv channels (e.g., Kv1.3, EAG family) help set the resting potential and modulate calcium influx; heightened K⁺ conductance tends to promote cell-cycle progression in lymphocytes and other cells (www.sciencedirect.com) (www.sciencedirect.com). Conversely, blocking K⁺ channels can arrest cell division or induce apoptosis (www.sciencedirect.com). KCNRG essentially mimics the effect of K⁺ channel blockers: its expression in LNCaP prostate cancer cells was shown to reduce the mitotic rate (www.sciencedirect.com), and in hematopoietic cell lines it causes growth suppression and morphological changes (discussed below) (pmc.ncbi.nlm.nih.gov). Thus, the biochemical role of KCNRG – binding K⁺ channel subunits and dampening their activity – has direct consequences for cellular physiology, especially in contexts where K⁺ currents drive proliferation or activation.

Notably, KCNRG belongs to the KCTD (Potassium Channel Tetramerization Domain-containing) protein family, which comprises 25 members in humans (pmc.ncbi.nlm.nih.gov). Many KCTD proteins use their BTB domains to recruit Cullin-3 (CUL3), functioning as adaptors in ubiquitin E3 ligase complexes that target specific substrates for degradation (pmc.ncbi.nlm.nih.gov). However, KCNRG appears to be an exception within this family. A comprehensive 2024 structural analysis (using AlphaFold modeling and bioinformatics) found that KCNRG’s BTB domain does not stably bind CUL3, unlike most KCTDs (pmc.ncbi.nlm.nih.gov). In the study’s assays, KCNRG failed to form a complex with CUL3, whereas related BTB domains (e.g. from KCTD6 or KCTD11) bound readily (pmc.ncbi.nlm.nih.gov). This suggests KCNRG’s function is independent of the ubiquitin-proteasome pathway; instead of tagging channels for degradation, it likely works by the physical assembly blockade described above. KCNRG and KCTD6 form a small sub-cluster of KCTDs with differing CUL3 binding properties, where KCTD6 can bind CUL3 but KCNRG cannot (pmc.ncbi.nlm.nih.gov) (www.mdpi.com). Evolutionarily, KCNRG is considered a somewhat atypical KCTD, sharing the conserved BTB/T1 domain but otherwise divergent in sequence from other family members (pmc.ncbi.nlm.nih.gov). Its unique inability to recruit CUL3 and its specialized role in K⁺ channel regulation set it apart from ubiquitin-dependent KCTDs.

Biological Role and Pathways

KCNRG’s chief biological role is tied to its regulation of cell excitability and proliferation via K⁺ channel modulation. By suppressing K⁺ currents, KCNRG can alter the membrane potential of cells. In excitable cells (like neurons or muscle), reducing K⁺ channel activity would tend to depolarize the cell or limit repolarization, potentially affecting excitability. However, KCNRG expression is not prominently noted in brain or muscle; instead, it is found in tissues like immune organs, testis, and lung (www.ncbi.nlm.nih.gov). Its function may therefore be more relevant to non-excitable cells such as lymphocytes or epithelial cells, where Kv channels serve roles in signaling and volume regulation rather than firing action potentials. In lymphocytes, Kv1.3 channels are crucial for sustaining the calcium signals needed for activation and proliferation. The discovery of KCNRG in the deletion hotspot of chronic lymphocytic leukemia (CLL) drew immediate interest to its role in the immune system. CLL cells (malignant B-lymphocytes) and other immature lymphocytes show upregulated K⁺ channel activity compared to resting cells (www.sciencedirect.com). K⁺ efflux helps maintain a negative membrane potential, which is required for calcium entry through CRAC channels during activation. By suppressing Kv currents, KCNRG would impair this calcium signaling cascade, thereby inhibiting lymphocyte activation and proliferation. This mechanistic link underlies its proposed tumor-suppressive effect (see next section). Indeed, the normal function of KCNRG may be to act as a check on cell activation or growth in contexts like the immune system or testis, although this remains to be fully elucidated.

Apart from cell cycle regulation, KCNRG might intersect with specific signaling pathways indirectly. No dedicated metabolic or signaling pathway for KCNRG is established yet, but its effects feed into pathways controlled by membrane voltage and ion flux. For instance, reduced K⁺ efflux can lead to depolarization and reduced driving force for Ca²⁺ entry, which can dampen pathways like NF-κB or MAPK that require calcium signals in immune cells. A 2010 study of KCNRG in leukemia cells observed increased apoptosis and changes in cell morphology upon KCNRG overexpression (pmc.ncbi.nlm.nih.gov), suggesting it may activate apoptotic pathways when it shuts down K⁺ channel-mediated survival signals. Additionally, hinting at broader pathway involvement, the gene lies in a genomic region (13q14) where several tumor suppressors including MIR15A/MIR16-1 (microRNAs that downregulate BCL2) reside (pubmed.ncbi.nlm.nih.gov). There is evidence that genes in this locus, including KCNRG, are co-regulated and functionally linked in common pathways (possibly related to NF-κB regulation and apoptosis) (pubmed.ncbi.nlm.nih.gov). For example, one hypothesis is that loss of KCNRG and these microRNAs together disrupts cellular homeostasis to promote CLL (pubmed.ncbi.nlm.nih.gov).

It’s also worth noting KCNRG’s role in the context of the immune system and autoimmunity. The fact that KCNRG becomes a target of autoantibodies in APS-1 and sepsis/ARDS implies that the protein might be upregulated or particularly immunogenic in lung tissue during inflammation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). KCNRG’s pulmonary expression could relate to a defensive role: K⁺ channels are key in fluid secretion and ciliary beating in airways, so a regulator of K⁺ channels might influence mucociliary clearance or epithelial responses. These connections remain speculative, as direct studies on KCNRG in normal physiology (e.g. knockout mouse models or signaling assays) are not extensively documented in the literature.

KCNRG in Disease: Tumor Suppressor Function and Clinical Significance

Role in Cancer (CLL, Lymphomas, and Solid Tumors)

KCNRG was originally identified as a candidate tumor suppressor gene because of its location in the most frequent deletion in chronic lymphocytic leukemia. Over 50% of CLL patients have a deletion of chromosome 13q14.3 (pubmed.ncbi.nlm.nih.gov), which pointed to this region harboring critical growth-suppressing genes. Initial sequencing efforts did not find inactivating point mutations in obvious genes, so researchers searched the genomic sequence and discovered KCNRG as a new gene in this interval (www.sciencedirect.com). Early functional tests immediately supported a tumor suppressor role: KCNRG re-expression curbed cell proliferation in cancer cell lines. A 2003 study by Ishida et al. (FEBS Letters) reported that transfecting KCNRG into LNCaP prostate cancer cells not only reduced K⁺ currents but also slowed cell growth (www.sciencedirect.com). By 2010, more direct evidence emerged in blood cancer models: stable overexpression of KCNRG in leukemia and myeloma cell lines (HL-60, RPMI-8226, etc.) caused a suppression of growth and induced apoptosis (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Cells with ectopic KCNRG also showed changes in size/shape and a decrease in migratory capacity in vitro (pmc.ncbi.nlm.nih.gov). These phenotypes mirror the effects of K⁺ channel blockers on cancer cells, linking KCNRG’s molecular function to anti-proliferative outcomes.

Crucially, the loss of KCNRG in tumors correlates with disease presence and progression. In CLL, the 13q14 deletion (which encompasses KCNRG) is not only common but often the sole abnormality in early-stage disease, suggesting it confers a growth advantage when heterozygously lost. The remaining KCNRG allele in CLL typically shows reduced expression (haploinsufficiency) (pubmed.ncbi.nlm.nih.gov). In one study, primary lymphoma samples had significantly lower KCNRG mRNA levels than normal lymphocytes, especially the shorter isoform transcript (pubmed.ncbi.nlm.nih.gov). This downregulation beyond simple gene dosage hints at epigenetic silencing or microRNA-mediated suppression in the cancer cells (pubmed.ncbi.nlm.nih.gov). Furthermore, no biallelic inactivating mutations have been found in KCNRG in CLL (pubmed.ncbi.nlm.nih.gov); instead, partial loss and reduced expression appear sufficient to affect cell behavior. This aligns with a model of KCNRG as a haploinsufficient tumor suppressor – even a 50% reduction in its activity might tilt the balance toward unchecked proliferation.

Beyond CLL, the involvement of KCNRG extends to other malignancies:

• Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM) – Similar to CLL, these B-cell tumors often harbor deletions in 13q14.3. Notably, 13q14 deletions are found in about 38% of MCL cases and ~54% of MM cases (pmc.ncbi.nlm.nih.gov). In non-CLL contexts, losing this region (and thus KCNRG and neighboring genes) has been associated with poor prognosis (pmc.ncbi.nlm.nih.gov). This suggests KCNRG loss may contribute to more aggressive disease in lymphoid cancers. The functional importance is supported by in vitro data: KCNRG overexpression can suppress growth of MM cells (e.g., RPMI-8226) and promote cell death (pubmed.ncbi.nlm.nih.gov). In at least one myeloma cell line, a frameshift mutation in KCNRG (a T deletion) was detected, likely disabling its function (pubmed.ncbi.nlm.nih.gov). These data implicate KCNRG as a relevant tumor suppressor across multiple B-cell neoplasms.

• Prostate Cancer – Deletions of 13q14 occur in a subset of prostate carcinomas as well (pmc.ncbi.nlm.nih.gov). The discovery paper specifically suggested KCNRG as a candidate prostate tumor suppressor because prostate cancer cell proliferation was sensitive to K⁺ channel blockade (www.sciencedirect.com), and introducing KCNRG mimicked that effect (www.sciencedirect.com). While 13q14 loss is not the predominant alteration in prostate cancer, its occurrence underscores that KCNRG inactivation may contribute to tumor development in the prostate in some cases (pmc.ncbi.nlm.nih.gov). Further research is needed to clarify its role in this context (e.g. whether KCNRG expression correlates with tumor grade or outcomes in prostate cancer).

• Hepatocellular Carcinoma (HCC) – A 2006 study systematically examined KCNRG in HCC tumors. Although 13q14 deletions are less common in carcinomas, loss of the KCNRG allele was detected in ~26.5% of HCC cases (17 of 64 informative cases) (www.nature.com). This loss of heterozygosity was significantly associated with more advanced disease: it correlated with presence of intrahepatic metastases, higher tumor grade, and later clinical stage (p<0.03 – 0.008 range) (www.nature.com). Additionally, KCNRG expression was absent in 22 out of 77 HCC tumor samples analyzed, indicating frequent transcriptional silencing (www.nature.com). Importantly, one missense mutation was identified in HCC: an Arg92→His substitution in the BTB domain (www.nature.com). This single-residue change impaired KCNRG’s function – when the mutant form was expressed in liver cells, it had significantly weaker growth-suppressive effect compared to wild-type KCNRG (www.nature.com). The Arg92 residue lies within the conserved BTB/T1 domain, so its alteration likely disrupts KCNRG’s ability to oligomerize or bind K⁺ channel partners. The HCC findings reinforce that genetic or epigenetic inactivation of KCNRG can contribute to tumorigenesis. The consistent pattern across cancers is that loss of KCNRG gives cells a proliferative and survival advantage (conversely, restoring KCNRG restrains growth).

• Other Cancers – There are indications that 13q14.3 loss (and by extension KCNRG loss) may occur in other malignancies as well. For instance, deletions in this region have been noted in subsets of gastrointestinal stromal tumors (GIST) (pmc.ncbi.nlm.nih.gov). Large-scale sequencing efforts (TCGA/COSMIC databases) have occasionally found KCNRG mutations in cancers, but these are relatively rare. Aside from the HCC mutation mentioned, KCNRG is not a hotspot for recurrent point mutations in common cancers, supporting the idea that deletion or downregulation is the main mechanism of disruption. A 2021 review on KCTD proteins in cancer highlighted KCNRG as unique among largely uncharacterized KCTDs because its role in cancer is already documented (pmc.ncbi.nlm.nih.gov). The authors noted KCNRG as a negative cell-growth regulator whose loss (via 13q14 deletion) likely contributes to the pathogenesis of CLL and MM (pmc.ncbi.nlm.nih.gov). They also speculated that KCNRG might have broader tumor-suppressive roles yet to be fully explored in other cancers (pmc.ncbi.nlm.nih.gov). Given the evidence, KCNRG is increasingly regarded as part of a multigenic tumor suppressor unit at 13q14, working in concert with other genes (like DLEU2 and miR-15a/16-1) to keep cell proliferation in check (pubmed.ncbi.nlm.nih.gov). The loss of this unit is a driver of malignancy in CLL and possibly other tumors.

Clinical and Diagnostic Implications

The link between KCNRG and disease yields several real-world applications:

• Biomarker for Cancer: Detection of 13q14 deletions is routine in CLL diagnostics; FISH cytogenetics or SNP arrays frequently test for this deletion as it has prognostic implications. While the prognostic impact in CLL is partly due to the miR-15a/16-1 loss, KCNRG’s absence may also be contributory. Some studies have suggested that CLL cases with 13q14 deletion (hence KCNRG haploinsufficiency) have distinct gene expression profiles and better outcomes than other cytogenetic subgroups, although they still constitute the majority of cases (pubmed.ncbi.nlm.nih.gov). In multiple myeloma, 13q deletions (including KCNRG) portend a poorer prognosis (pmc.ncbi.nlm.nih.gov), so identifying KCNRG loss could help stratify patients. Moreover, the 2006 HCC study implies KCNRG could be a prognostic marker in liver cancer: loss of the gene was associated with more aggressive tumor behavior (metastasis and high grade) (www.nature.com). If further validated, KCNRG expression status might be useful to gauge tumor aggressiveness in HCC or other solid tumors.

• Therapeutic angle: Understanding KCNRG’s function opens up possible therapeutic considerations. One idea is that augmenting KCNRG activity (or mimicking it) might suppress tumor cell growth, similar to using pharmacologic K⁺ channel blockers. For example, Kv1.3 channel blockers are being explored as immune modulators in autoimmune disease and as anti-cancer agents for certain leukemias. KCNRG, as an endogenous inhibitor of Kv channels, could be seen as a natural analog. While delivering a protein is not straightforward, gene therapy or small molecules that enhance KCNRG expression in tumor cells could, in theory, reduce proliferative capacity. Conversely, in conditions where KCNRG might be overactive or detrimental (none are well characterized yet), one might consider inhibiting it. Right now, such therapeutic applications remain speculative since no drugs specifically target KCNRG and its regulatory network.

• Autoantibody marker: In APS-1 (autoimmune polyendocrine syndrome type 1), testing for anti-KCNRG antibodies has become a way to identify patients at risk for autoimmune lung disease (pmc.ncbi.nlm.nih.gov). Approximately 7 out of 8 APS-1 patients with unexplained respiratory symptoms had anti-KCNRG autoantibodies, whereas such antibodies were virtually absent in APS-1 patients without lung involvement (pmc.ncbi.nlm.nih.gov). This strong association means that an autoantibody test for KCNRG can serve as a diagnostic clue for APS-1 related pneumonitis. Similarly, in critical care settings, the presence of anti-KCNRG antibodies in ARDS or sepsis could be an interesting indicator of the extent of lung injury or a patient’s immune status (pmc.ncbi.nlm.nih.gov). Burbelo et al. (2010) found that 57% of ARDS patients and 46% of severe sepsis patients developed new autoantibodies during their illness, with KCNRG being the most frequently targeted autoantigen in their panel (pmc.ncbi.nlm.nih.gov). This suggests that KCNRG is highly immunogenic when lung tissues are inflamed or damaged. While these autoantibodies are likely a consequence of tissue damage rather than a cause, they highlight KCNRG’s prominence in lung tissue. Clinically, monitoring such autoantibodies might one day help in understanding or even predicting acute lung injury trajectories, though more research is needed.

• Research tool: KCNRG itself can be used as a tool to study K⁺ channel biology. Its specific interaction with Kv channel subunits provides a means to probe channel assembly. Researchers have used KCNRG overexpression or knockdown in cell models to see how it alters the trafficking of Kv1 channels (www.genecards.org). It could be used experimentally to dissect which Kv subtypes are sensitive to its regulation. Furthermore, the distinct difference between KCNRG and most KCTD proteins (in terms of CUL3 binding) makes it an interesting model for studying BTB domain protein interactions – essentially, KCNRG is a BTB-domain protein that chose a channel-regulatory route instead of ubiquitin-ligase route. This could guide structure-function analyses; for instance, swapping domains between KCNRG and a Cullin-binding KCTD might elucidate the structural requirements for each function.

Expert Perspectives and Future Directions

Experts in the field view KCNRG as a partially characterized but significant regulator at the crossroads of ion channel physiology and cancer biology. In a 2021 review of KCTD family proteins, Angrisani et al. highlighted KCNRG as an outlier KCTD with a known role in cancer suppression (pmc.ncbi.nlm.nih.gov). They noted that while many KCTDs are still mysterious, KCNRG stands out because of substantial evidence linking it to tumor suppression in CLL and MM (pmc.ncbi.nlm.nih.gov). The authors point out that enforced KCNRG expression curtails proliferation and survival of leukemia cells, supporting its function as a growth brake (pmc.ncbi.nlm.nih.gov). They also emphasize the correlation of 13q14 deletions with these cancers, underscoring the clinical relevance of losing KCNRG (pmc.ncbi.nlm.nih.gov). In the broader context, there is a growing appreciation that ion channels and their regulators are important in oncology. KCNRG exemplifies this by showing how a modulator of ion flux can influence cell fate. Some oncology researchers propose that targeting ion channels (the so-called “ion channelopathies of cancer”) could open new therapeutic avenues. In that light, KCNRG could be both a biomarker of channel activity in tumors and a model for developing molecules that disrupt channel assembly in cancer cells.

From the immunology perspective, experts were intrigued by the discovery of KCNRG as a dominant autoantigen in APS-1 lung disease (pmc.ncbi.nlm.nih.gov). This revealed an unexpected tissue-restricted expression pattern (bronchial epithelium) and suggested that tolerance to this protein is particularly dependent on the AIRE gene (since APS-1 patients have AIRE mutations). It raises the question of what role KCNRG plays in the lung. Pulmonologists and immunologists might speculate that if KCNRG regulates potassium channels in bronchiolar cells, it could affect processes like electrolyte transport in airway secretions or the proliferation of airway epithelium. There is also an interest in whether KCNRG or anti-KCNRG immune responses contribute to pulmonary conditions outside of APS-1 (for example, could they occur in idiopathic pulmonary fibrosis or other autoimmune lung diseases?). So far, such antibodies have mainly been described in APS-1 and in the context of acute lung injury (ARDS) (pmc.ncbi.nlm.nih.gov), but this remains an area for future investigation.

Moving forward, research in 2023-2024 and beyond is focusing on a few key areas regarding KCNRG:

• Structural Biology: With advances like AlphaFold, predictions of KCNRG’s 3D structure (especially its BTB domain) have become available (pmc.ncbi.nlm.nih.gov). Validating these models experimentally (e.g. by crystallography or cryo-EM) could confirm how KCNRG interacts with Kv channel peptides. The 2024 Int. J. Mol. Sci. analysis provided structural models for all KCTD–CUL3 interfaces and found KCNRG to lack a stable interface (pmc.ncbi.nlm.nih.gov), reinforcing the notion that KCNRG’s BTB surface is oriented for channel subunits rather than Cullin. Understanding the precise interaction surfaces on KCNRG that bind channel subunits could facilitate the design of peptides or small molecules that mimic KCNRG’s effect by disrupting channel assembly.

• In vivo studies: To date, much of what we know comes from cell-based assays and tumor correlations. A logical next step is to study Kcnrg in animal models. A mouse ortholog of KCNRG exists (sometimes referenced by partial clone names like Dltet or Gm745) (geneglobe.qiagen.com). Generating Kcnrg knockout mice could reveal any phenotype in normal physiology – for instance, do such mice have lymphocyte hyperproliferation, or subtle immunological abnormalities? Conversely, a transgenic mouse overexpressing KCNRG in B-cells might show an immunosuppressed phenotype (e.g. smaller germinal centers, impaired antibody responses). Such models would cement KCNRG’s role in vivo. Similarly, crossing a Kcnrg knockout with a cancer-prone model could test if tumors form more readily. Considering the multi-gene nature of the 13q14 region, one challenge is that deleting only Kcnrg may not recapitulate the full CLL-like phenotype (in CLL, often miR-15/16 are co-deleted). Still, it would clarify KCNRG’s individual contribution.

• Cancer genomics and therapy: Ongoing cancer sequencing projects might shed more light on incidence of KCNRG alterations. If, for example, certain lymphoma subtypes without 13q deletion still silence KCNRG (via methylation), it could indicate a broader relevance. Epigenetic drugs or gene reactivation strategies could then be tested to restore KCNRG in tumors. Meanwhile, pharmacologists might explore whether ion channel inhibitors could substitute for KCNRG function in KCNRG-deficient cancers. Since KCNRG specifically downregulates Kv channels, drugs targeting those same channels (like Kv1.3 blockers) might preferentially harm KCNRG-null cancer cells. This approach is speculative but aligns with personalized medicine: patients whose tumors lack KCNRG (and thus have heightened K⁺ channel activity) might respond to K⁺ channel-blocking compounds.

In summary, KCNRG is a distinctive protein that links ion channel regulation to cell proliferation control. Our current understanding is that KCNRG serves as a potassium channel “brake”, keeping cellular K⁺ currents – and thus proliferative signaling – in check. It is predominantly a cytosolic protein with a conserved oligomerization domain that hijacks K⁺ channel assembly processes. Loss of KCNRG unleashes K⁺ channel activity, contributing to uncontrolled cell growth as seen in leukemia, lymphoma, and other cancers. Conversely, high KCNRG activity can dampen cell growth and even trigger cell death, which is why cells normally keep a balance in its expression. Recent research (up to 2024) has reinforced its tumor suppressor credentials and clarified that, unlike many cousins in the KCTD family, KCNRG operates independently of ubiquitin ligases, focusing on channel modulation. As an antigen, it has provided a window into autoimmune lung pathology, stressing its tissue-specific expression. Going forward, KCNRG stands as both a subject of fundamental interest – illuminating how channel regulators impact disease – and a potential target for clinical intervention, whether by measuring its loss as a cancer biomarker or by emulating its function to achieve therapeutic K⁺ channel inhibition.

References: The information above is drawn from current scientific literature and databases, including gene/protein databases (NCBI Gene, UniProt) and a number of key studies. Original discovery and characterization of KCNRG were reported in 2003 (www.sciencedirect.com) (www.sciencedirect.com), with functional tumor suppressor evidence expanded in 2010 (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). The gene’s involvement in HCC was detailed in 2006 (www.nature.com) (www.nature.com). Reviews by expert researchers (e.g., Angrisani et al., 2021 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)) and recent analyses (Balasco et al., 2024 (pmc.ncbi.nlm.nih.gov)) have been cited to provide up-to-date context. Publication dates and sources have been included with each citation for verification.

Citations

1. AnnotationURLCitation(end_index=362, start_index=272, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=,4')
2. AnnotationURLCitation(end_index=507, start_index=363, title='KCNRG potassium channel regulator [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/283518#:~:text=Summary%20This%20gene%20encodes%20a,24%20other%20tissues%20See%20more')
3. AnnotationURLCitation(end_index=776, start_index=632, title='KCNRG potassium channel regulator [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/283518#:~:text=Summary%20This%20gene%20encodes%20a,24%20other%20tissues%20See%20more')
4. AnnotationURLCitation(end_index=1057, start_index=907, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=encoded%20by%20mRNAs%20AY129654%20and,gated%20K')
5. AnnotationURLCitation(end_index=1297, start_index=1147, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=encoded%20by%20mRNAs%20AY129654%20and,gated%20K')
6. AnnotationURLCitation(end_index=1640, start_index=1496, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20the%20newly%20found%20gene,gated%20K')
7. AnnotationURLCitation(end_index=1950, start_index=1806, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20the%20newly%20found%20gene,gated%20K')
8. AnnotationURLCitation(end_index=2236, start_index=2055, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=match%20at%20L214%20channels%20%28Fig,structure%20in%20the%20KCNRG%20suggested')
9. AnnotationURLCitation(end_index=2364, start_index=2237, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=voltage,cell%20potassium')
10. AnnotationURLCitation(end_index=2617, start_index=2467, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=encoded%20by%20mRNAs%20AY129654%20and,gated%20K')
11. AnnotationURLCitation(end_index=3234, start_index=3144, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=,4')
12. AnnotationURLCitation(end_index=3463, start_index=3319, title='KCNRG potassium channel regulator [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/283518#:~:text=Summary%20This%20gene%20encodes%20a,24%20other%20tissues%20See%20more')
13. AnnotationURLCitation(end_index=3795, start_index=3651, title='KCNRG potassium channel regulator [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/283518#:~:text=This%20gene%20encodes%20a%20protein,24%20other%20tissues%20See%20more')
14. AnnotationURLCitation(end_index=4092, start_index=3912, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=In%20this%20report%2C%20we%20describe,and%20some%20tumor%20tissues%20analyzed')
15. AnnotationURLCitation(end_index=4210, start_index=4093, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20voltage,3')
16. AnnotationURLCitation(end_index=4559, start_index=4368, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
17. AnnotationURLCitation(end_index=4962, start_index=4771, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
18. AnnotationURLCitation(end_index=5434, start_index=5267, title='Rapid induction of autoantibodies during ARDS and septic shock - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970592/#:~:text=From%20screening%20patient%20plasma%2C%2057,the%20last%20serum%20sample%20collected')
19. AnnotationURLCitation(end_index=5773, start_index=5582, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
20. AnnotationURLCitation(end_index=6238, start_index=6081, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=Inhibits%20potassium%20fluxes%20in%20cells,%28%20KCNRG_HUMAN%2CQ8N5I3')
21. AnnotationURLCitation(end_index=6659, start_index=6519, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=Signaling%20pathcards,of%20this%20gene%20is%20KCTD12')
22. AnnotationURLCitation(end_index=7131, start_index=6975, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=isoforms%20that%20are%20expressed%20in,cell%20chronic')
23. AnnotationURLCitation(end_index=7469, start_index=7313, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=isoforms%20that%20are%20expressed%20in,cell%20chronic')
24. AnnotationURLCitation(end_index=8026, start_index=7899, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=voltage,cell%20potassium')
25. AnnotationURLCitation(end_index=8208, start_index=8027, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=match%20at%20L214%20channels%20%28Fig,structure%20in%20the%20KCNRG%20suggested')
26. AnnotationURLCitation(end_index=8518, start_index=8374, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20the%20newly%20found%20gene,gated%20K')
27. AnnotationURLCitation(end_index=8919, start_index=8792, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=voltage,cell%20potassium')
28. AnnotationURLCitation(end_index=9358, start_index=9208, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=encoded%20by%20mRNAs%20AY129654%20and,gated%20K')
29. AnnotationURLCitation(end_index=9691, start_index=9534, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=Inhibits%20potassium%20fluxes%20in%20cells,%28%20KCNRG_HUMAN%2CQ8N5I3')
30. AnnotationURLCitation(end_index=10030, start_index=9873, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=Inhibits%20potassium%20fluxes%20in%20cells,%28%20KCNRG_HUMAN%2CQ8N5I3')
31. AnnotationURLCitation(end_index=10507, start_index=10323, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=In%20several%20cell%20types%2C%20enhanced,high%20expression%20of%20EAG%20channels')
32. AnnotationURLCitation(end_index=10888, start_index=10704, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=In%20several%20cell%20types%2C%20enhanced,high%20expression%20of%20EAG%20channels')
33. AnnotationURLCitation(end_index=11074, start_index=10889, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=cancer%2C%20LNCaP%20cells%2C%20the%20K,cell%20proliferation%20by%20suppressing%20K')
34. AnnotationURLCitation(end_index=11343, start_index=11158, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=cancer%2C%20LNCaP%20cells%2C%20the%20K,cell%20proliferation%20by%20suppressing%20K')
35. AnnotationURLCitation(end_index=11677, start_index=11492, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=cancer%2C%20LNCaP%20cells%2C%20the%20K,cell%20proliferation%20by%20suppressing%20K')
36. AnnotationURLCitation(end_index=11945, start_index=11784, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
37. AnnotationURLCitation(end_index=12485, start_index=12316, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=The%20human%20family%20of%20Potassium,between%20family%20members%2C%20capability%20to')
38. AnnotationURLCitation(end_index=12821, start_index=12665, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=the%20BTB%20domains%20of%20the,unable%20to%20bind%20Cul3%2C%20establish')
39. AnnotationURLCitation(end_index=13189, start_index=13055, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=KCTD15%5E%7BBTB%28A56,Stable%20complex%20detected')
40. AnnotationURLCitation(end_index=13460, start_index=13326, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=KCTD15%5E%7BBTB%28A56,Stable%20complex%20detected')
41. AnnotationURLCitation(end_index=13928, start_index=13794, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=KCTD15%5E%7BBTB%28A56,Stable%20complex%20detected')
42. AnnotationURLCitation(end_index=14046, start_index=13929, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3', type='url_citation', url='https://www.mdpi.com/1422-0067/25/3/1881#:~:text=,exhibit%20different%20Cul3%20binding%20properties')
43. AnnotationURLCitation(end_index=14371, start_index=14212, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=The%20KCTD%20proteins%20that%20are,are%20in%20general%20not%20characterized')
44. AnnotationURLCitation(end_index=15196, start_index=15052, title='KCNRG potassium channel regulator [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/283518#:~:text=This%20gene%20encodes%20a%20protein,24%20other%20tissues%20See%20more')
45. AnnotationURLCitation(end_index=15922, start_index=15805, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20voltage,3')
46. AnnotationURLCitation(end_index=17209, start_index=17048, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
47. AnnotationURLCitation(end_index=17636, start_index=17511, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=Loss%20of%20a%20critical%20region,3%20in%20non')
48. AnnotationURLCitation(end_index=17937, start_index=17812, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=Loss%20of%20a%20critical%20region,3%20in%20non')
49. AnnotationURLCitation(end_index=18237, start_index=18063, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=malignant%20cells%20that%20involves%20asynchronous,the%20underlying%20pathomechanism%20of%20CLL')
50. AnnotationURLCitation(end_index=18715, start_index=18524, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
51. AnnotationURLCitation(end_index=18883, start_index=18716, title='Rapid induction of autoantibodies during ARDS and septic shock - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970592/#:~:text=From%20screening%20patient%20plasma%2C%2057,the%20last%20serum%20sample%20collected')
52. AnnotationURLCitation(end_index=19785, start_index=19660, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=Loss%20of%20a%20critical%20region,3%20in%20non')
53. AnnotationURLCitation(end_index=20224, start_index=20045, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=Previously%20it%20was%20demonstrated%20that,7%5D.%20Four%20candidate%20genes')
54. AnnotationURLCitation(end_index=20653, start_index=20536, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20voltage,3')
55. AnnotationURLCitation(end_index=21020, start_index=20865, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=stable%20overexpression%20of%20KCNRG%20isoforms,at%20least%20in%20a%20subset')
56. AnnotationURLCitation(end_index=21182, start_index=21021, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
57. AnnotationURLCitation(end_index=21450, start_index=21289, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
58. AnnotationURLCitation(end_index=22112, start_index=21970, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=Three%20MM%20cell%20lines%20and,in%20a%20subset%20of%20patients')
59. AnnotationURLCitation(end_index=22404, start_index=22262, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=Three%20MM%20cell%20lines%20and,in%20a%20subset%20of%20patients')
60. AnnotationURLCitation(end_index=22696, start_index=22535, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=Engl%20J%20Med%202000%3B343%3A1910%20,where%20several%20tumor%20suppressor%20genes')
61. AnnotationURLCitation(end_index=22908, start_index=22783, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=Loss%20of%20a%20critical%20region,3%20in%20non')
62. AnnotationURLCitation(end_index=23599, start_index=23463, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=migration%20capacity%20,of%20CLL%20and%20MM%20tumors')
63. AnnotationURLCitation(end_index=23860, start_index=23724, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=migration%20capacity%20,of%20CLL%20and%20MM%20tumors')
64. AnnotationURLCitation(end_index=24258, start_index=24103, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=stable%20overexpression%20of%20KCNRG%20isoforms,at%20least%20in%20a%20subset')
65. AnnotationURLCitation(end_index=24527, start_index=24385, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=Three%20MM%20cell%20lines%20and,in%20a%20subset%20of%20patients')
66. AnnotationURLCitation(end_index=24807, start_index=24714, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=13q14,128')
67. AnnotationURLCitation(end_index=25164, start_index=24979, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=cancer%2C%20LNCaP%20cells%2C%20the%20K,cell%20proliferation%20by%20suppressing%20K')
68. AnnotationURLCitation(end_index=25326, start_index=25209, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20voltage,3')
69. AnnotationURLCitation(end_index=25609, start_index=25516, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=13q14,128')
70. AnnotationURLCitation(end_index=26170, start_index=26014, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=KCNRG%20missense%20mutation%2C%20CGT%E2%86%92CAT%20,of%20expression%20of%20the%20KCNRG')
71. AnnotationURLCitation(end_index=26537, start_index=26381, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=KCNRG%20missense%20mutation%2C%20CGT%E2%86%92CAT%20,of%20expression%20of%20the%20KCNRG')
72. AnnotationURLCitation(end_index=26831, start_index=26675, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=Moreover%2C%20the%20allelic%20loss%20was,development%20and%2For%20progression%20of%20a')
73. AnnotationURLCitation(end_index=27091, start_index=26939, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=The%20potassium%20channels%20are%20ubiquitous,Interestingly%2C%20the%20suppressive')
74. AnnotationURLCitation(end_index=27404, start_index=27281, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=allelic%20loss%20and%20expression%20patterns,positive')
75. AnnotationURLCitation(end_index=28170, start_index=28077, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=13q14,128')
76. AnnotationURLCitation(end_index=28834, start_index=28672, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=Among%20them%2C%20KCNRG%20is%20the,cancer%20is%20known%2C%20albeit%20partially')
77. AnnotationURLCitation(end_index=29142, start_index=28981, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
78. AnnotationURLCitation(end_index=29397, start_index=29261, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=migration%20capacity%20,of%20CLL%20and%20MM%20tumors')
79. AnnotationURLCitation(end_index=29777, start_index=29612, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=malignant%20cells%20that%20involves%20asynchronous,3%20candidate%20genes%20will%20shed')
80. AnnotationURLCitation(end_index=30654, start_index=30529, title='Chronic lymphocytic leukemia and 13q14: miRs and more - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19347735/#:~:text=Loss%20of%20a%20critical%20region,3%20in%20non')
81. AnnotationURLCitation(end_index=30872, start_index=30736, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=migration%20capacity%20,of%20CLL%20and%20MM%20tumors')
82. AnnotationURLCitation(end_index=31275, start_index=31119, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=KCNRG%20missense%20mutation%2C%20CGT%E2%86%92CAT%20,of%20expression%20of%20the%20KCNRG')
83. AnnotationURLCitation(end_index=32714, start_index=32523, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
84. AnnotationURLCitation(end_index=33105, start_index=32914, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
85. AnnotationURLCitation(end_index=33592, start_index=33425, title='Rapid induction of autoantibodies during ARDS and septic shock - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970592/#:~:text=From%20screening%20patient%20plasma%2C%2057,the%20last%20serum%20sample%20collected')
86. AnnotationURLCitation(end_index=33977, start_index=33810, title='Rapid induction of autoantibodies during ARDS and septic shock - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970592/#:~:text=From%20screening%20patient%20plasma%2C%2057,the%20last%20serum%20sample%20collected')
87. AnnotationURLCitation(end_index=34832, start_index=34675, title='KCNRG Gene - GeneCards | KCNRG Protein | KCNRG Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNRG#:~:text=Inhibits%20potassium%20fluxes%20in%20cells,%28%20KCNRG_HUMAN%2CQ8N5I3')
88. AnnotationURLCitation(end_index=35913, start_index=35751, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=Among%20them%2C%20KCNRG%20is%20the,cancer%20is%20known%2C%20albeit%20partially')
89. AnnotationURLCitation(end_index=36226, start_index=36065, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
90. AnnotationURLCitation(end_index=36543, start_index=36382, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
91. AnnotationURLCitation(end_index=36808, start_index=36672, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=migration%20capacity%20,of%20CLL%20and%20MM%20tumors')
92. AnnotationURLCitation(end_index=37660, start_index=37469, title='Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2648890/#:~:text=putative%20potassium%20channel%20regulator%20,diagnosis%2C%20characterization%2C%20and%20understanding%20of')
93. AnnotationURLCitation(end_index=38675, start_index=38508, title='Rapid induction of autoantibodies during ARDS and septic shock - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970592/#:~:text=From%20screening%20patient%20plasma%2C%2057,the%20last%20serum%20sample%20collected')
94. AnnotationURLCitation(end_index=39167, start_index=38973, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=KCTD%20%28%28K%29potassium%20Channel%20Tetramerization%20Domain,demonstrate%20the%20impressive%20ability%20of')
95. AnnotationURLCitation(end_index=39576, start_index=39442, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=KCTD15%5E%7BBTB%28A56,Stable%20complex%20detected')
96. AnnotationURLCitation(end_index=40285, start_index=40149, title='KCNRG [Human] | GeneGlobe', type='url_citation', url='https://geneglobe.qiagen.com/us/knowledge/gene/ENSG00000198553#:~:text=Aliases%20%20,Human%2C%20Homo%20sapiens')
97. AnnotationURLCitation(end_index=43656, start_index=43476, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=In%20this%20report%2C%20we%20describe,and%20some%20tumor%20tissues%20analyzed')
98. AnnotationURLCitation(end_index=43774, start_index=43657, title='A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3 - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0014579303002114#:~:text=As%20voltage,3')
99. AnnotationURLCitation(end_index=43990, start_index=43835, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=stable%20overexpression%20of%20KCNRG%20isoforms,at%20least%20in%20a%20subset')
100. AnnotationURLCitation(end_index=44133, start_index=43991, title='Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20237900/#:~:text=Three%20MM%20cell%20lines%20and,in%20a%20subset%20of%20patients')
101. AnnotationURLCitation(end_index=44309, start_index=44186, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=allelic%20loss%20and%20expression%20patterns,positive')
102. AnnotationURLCitation(end_index=44466, start_index=44310, title='Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas | Experimental & Molecular Medicine', type='url_citation', url='https://www.nature.com/articles/emm200630#:~:text=Moreover%2C%20the%20allelic%20loss%20was,development%20and%2For%20progression%20of%20a')
103. AnnotationURLCitation(end_index=44692, start_index=44530, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=Among%20them%2C%20KCNRG%20is%20the,cancer%20is%20known%2C%20albeit%20partially')
104. AnnotationURLCitation(end_index=44854, start_index=44693, title='The emerging role of the KCTD proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8127222/#:~:text=KCNRG%20overexpression%20in%20leukemia%20cell,play%20a%20relevant%20role%20in')
105. AnnotationURLCitation(end_index=45034, start_index=44900, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=KCTD15%5E%7BBTB%28A56,Stable%20complex%20detected')